SCHEMBL6795960

SCHEMBL6795960

O=C1OC(c2ccc(Nc3ccccc3C(=O)O)cc2)=N/C1=C/c1ccc(Cl)c(Cl)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK2A2 P19784 3/20 0.51
CSNK2B P67870 3/20 0.51
CSNK2A1 P68400 3/20 0.51
MEN1 O00255 4/20 0.50
KMT2A Q03164 4/20 0.50
RECQL P46063 1/20 0.50
BLM P54132 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
ALOX5 P09917 1/20 0.44
KDM4E B2RXH2 1/20 0.43
NPC1 O15118 1/20 0.43
ALDH1A1 P00352 1/20 0.43
MAPT P10636 1/20 0.43
NFKB1 P19838 1/20 0.43
RAB9A P51151 1/20 0.43
GFER P55789 1/20 0.43
NFKB2 Q00653 1/20 0.43
RELA Q04206 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
TTR P02766 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6795962 1.00 CSNK2A2 (0.51) CSNK2A2CSNK2BCSNK2A1MEN1KMT2A
SCHEMBL6800601 0.86 CSNK2A2 (0.64) CSNK2A2CSNK2BCSNK2A1MEN1KMT2A
SCHEMBL6800599 0.86 CSNK2A2 (0.64) CSNK2A2CSNK2BCSNK2A1MEN1KMT2A
SCHEMBL6796767 0.83 CSNK2A2 (0.53) CSNK2A2CSNK2BCSNK2A1MEN1KMT2A
SCHEMBL6796766 0.83 CSNK2A2 (0.53) CSNK2A2CSNK2BCSNK2A1MEN1KMT2A
SCHEMBL6794321 0.81 CSNK2A2 (0.72) CSNK2A2CSNK2BCSNK2A1MEN1KMT2A
SCHEMBL6794318 0.81 CSNK2A2 (0.72) CSNK2A2CSNK2BCSNK2A1MEN1KMT2A
SCHEMBL6795309 0.81 PLCG2 (0.60) CSNK2A2CSNK2BCSNK2A1MEN1KMT2A
SCHEMBL6795306 0.81 PLCG2 (0.60) CSNK2A2CSNK2BCSNK2A1MEN1KMT2A
SCHEMBL6790633 0.80 MASP2 (0.48) CSNK2A2CSNK2BCSNK2A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040180943-A1 Oxazolone analogs as amyloid aggregation inhibitors and for the treatment of alzheimer's disease and disorders related to amyloidosis WARNER-LAMBERT COMPANY LLC 2004-09-16 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180943-A1 Oxazolone analogs as amyloid aggregation inhibitors and for the treatment of alzheimer's disease and disorders related to amyloidosis APP, PSEN1, PSEN2 CSNK2A2 1982/4885CSNK2B 1874/4885CSNK2A1 1986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.